エドガーで原本を確認する
|
Date: May 19, 2025
|
|||
|
CREDICORP LTD.
(Registrant)
|
|||
|
By:
|
/s/ Guillermo Morales
|
||
|
Guillermo Morales
|
|||
|
Authorized Representative
|
|||
| (i) |
A statement dated March 26, 20252, in which SANNA reported, among other things, that on Monday, March 24, the pharmaceutical laboratory Medifarma made public that it had marketed a defective batch of saline solution and
proceeded to withdraw it from its distribution points. They also reported that two patients at Clínica SANNA Trujillo, who were administered the saline solution from the mentioned batch, had died. Additionally, they indicated that two
patients at Clínica SANNA San Borja were in critical health condition for the same reason and that they had learned that a person who had initially been treated at that institution with the same saline solution, and later transferred to
another health center, had also died.
|
| (ii) |
The RPP website on March 26, 20253, titled "Clínica Sanna confirms that two more people died after receiving saline solution observed by the Ministry of Health (Minsa)".
|
| (iii) |
Semana Economica on March 27, 20254, titled "Clínica Sanna confirmed two deaths and serious patients due to defective Medifarma saline solution".
|
| (iv) |
Press Release No. 007-2025 dated March 29, 20255, in which the Ministry of Health – MINSA, through its Attorney General's Office, reported having "criminally denounced Clínica SANNA and those responsible for failing to report in
a timely manner (within the required 24 hours) the first serious adverse reaction that resulted in death, notifying it only a month later".
|
| (v) |
The Infobae website on April 1, 20256, titled "Ministry of Health (Minsa): Sanna alerted about the death of a patient due to defective Medifarma saline solution one month after the death".
|
| (vi) |
Diario Gestion on April 1, 20257, titled "Defective saline solution: SANNA gives its version of why its Trujillo clinic could not identify it".
|
| (vii) |
The Ojo Publico website on April 13, 20258, titled "Medifarma case: the defective saline solution that exposed cracks in the health system".
|
| (viii) |
The RPP website on April 17, 20259, titled "Nurse who was in critical condition after being administered saline solution at Clínica Sanna dies".
|
| (ix) |
El Comercio website on April 19, 202510, titled "Architect dies after being in brain death for a month: the number of victims of Medifarma's defective saline solution rises to 7".
|
| 1. |
Explain the reasons why your representative has not yet disclosed as a relevant event all the information related to the events that occurred at Clínica SANNA San Borja and Clínica SANNA Trujillo.
|
| 2. |
Disclose all the information related to the administration of defective saline solution to various patients in the SANNA Clinic Network.
|
| 3. |
Confirm and/or clarify all the information about the judicial process initiated by the Ministry of Health (MINSA) against the SANNA Clinic Network.
|
| 4. |
Inform whether there are any administrative processes initiated by Peruvian State authorities against any of the clinics in the SANNA Clinic Network, belonging to your economic group, or against their respective officials.
|
| 5. |
Provide detailed information on all the agreements adopted by the governing bodies of your representative or the companies in your economic group in relation to the serious events indicated. If no agreement has been adopted, inform this
situation, indicating the reasons.
|
| 6. |
Provide all information related to the economic/financial impact generated by the aforementioned events and their consequences on your representative and/or the companies in your economic group, as well as the measurement of such impact to
date.
|
| 7. |
Provide all information related to the measurement of the reputational impact on your representative and the companies in your economic group.
|
| 8. |
Provide detailed information on any other relevant additional information on the matters of this official letter.
|
|
Ref.:
|
File No. 2025017716
Official Letter No. 2302-2025-SMV/11.1
Letter dated April 24, 2025
|
| (i) |
Official Letter No. 2302-2025-SMV/11.1 (hereinafter, “Official Letter No. 2302”), through which the General Office of Conduct Supervision (IGSC) made several requests for information to Credicorp Ltd. (hereinafter, “Credicorp”) regarding
the serious incidents that occurred within the SANNA Clinic Network, related to the administration of defective saline solution to various patients, which resulted in fatalities. Additionally, Credicorp was requested to immediately disclose
the Official Letter No. 2302 as a material event, notwithstanding the deadline granted for responding to the information requests.
|
| (ii) |
Letter dated April 24, 2025, in which Credicorp responded to Official Letter No. 2302.
|
|
April 24, 2025
SUPERINTENDENCY OF THE SECURITIES MARKET – SMV
Attn.: Mr. Alix Godos – Head of Conduct Supervision
General Office of Conduct Supervision
Ref.: Official Letter No. 2302-2025-SMV/11.1
Dear Sirs,
In response to the referenced Official Letter, we consider that the entity best positioned to respond and inform the market regarding the matters indicated therein is Pacífico Compañía de
Seguros y Reaseguros S.A. (hereinafter, “Pacífico”), in its capacity as direct shareholder of Pacífico S.A. Entidad Prestadora de Salud, owner of La Esperanza del Perú S.A. (Clínica SANNA San Borja) and Clínica Sánchez Ferrer S.A. (Clínica
SANNA Trujillo). Accordingly, we respectfully request that this Superintendency redirect the aforementioned request to Pacífico so that it may address the matter. It is worth noting that Pacífico is a company whose shares are registered in
the Public Registry of the Securities Market.
Sincerely,
CREDICORP LTD.
|
| (iii) |
Letter dated April 28, 2025, through which Credicorp stated: “(…) we would like to reiterate our communication dated April 24, 2025, a copy of which is attached, and we remain attentive to your response at your earliest convenience.”
|
| Cc: |
Pacífico Compañía de Seguros y Reaseguros S.A.
Lima Stock Exchange S.A.
|